尽管有大量关于宫颈癌治疗策略的文献，但专门针对晚期、复发性或转移性 (A/R/M) 宫颈恶性肿瘤的免疫治疗的文献计量分析仍未得到探索。本研究旨在通过提供全面的概述来解决这一差距，其中包括一般特征、研究重点、进化轨迹以及该研究领域当前的新兴趋势。使用 Web of Science 核心合集进行了系统检索（ WOSCC）来识别 2000 年至 2022 年间发表的与 A/R/M 宫颈癌相关的文章。Citespace 和 VOS 查看器是用于识别研究焦点、有趣的未来模式以及评估作者之间的贡献和共现的主要工具，共识别出 1,001 篇原创文章，涉及来自 66 个国家和 1,474 个机构的 6,387 名作者，发表在 366 种学术期刊上。美国的贡献最为显着。最多产的研究人员是来自莱顿大学医学中心的 Van der Burg SH。 《国际癌症杂志》和《癌症研究》分别被评为最具生产力和影响力的期刊。对共被引簇的分析突出了 25 个簇，主要关注潜在的预测生物标志物、基于树突状细胞的肿瘤疫苗、治疗性 HPV 疫苗、基于肽的癌症疫苗、肿瘤免疫微环境和过继细胞转移 (ACT)。通过关键词和参考突发检测揭示了 A/R/M 宫颈癌免疫治疗研究的最新重大趋势，包括 ACT、CAR-T 和免疫检查点抑制剂 (ICIs)。这项开创性的研究提供了 A/R/M 宫颈癌免疫治疗研究的详细情况。 /R/M 宫颈癌。它强调了全球合作的重要性，丰富了我们对 A/R/M 宫颈癌免疫学的理解，扩展了免疫疗法的潜在受益者，并探索了各种疗法的临床应用，包括治疗性疫苗、过继性细胞移植和 ICI，特别是与化疗、放疗和靶向治疗等既定治疗方法相结合。版权所有 © 2024 段、杨、王、张、付、李和尹。

Despite extensive literature on therapeutic strategies for cervical cancer, a bibliometric analysis specifically focused on immunotherapy for advanced, recurrent, or metastatic (A/R/M) cervical malignancies remains unexplored. This study aims to address this gap by presenting a comprehensive overview that includes general characteristics, research focal points, the trajectory of evolution, and current emerging trends in this under-researched area.A systematic search was conducted using the Web of Science Core Collection (WOSCC) to identify articles related to A/R/M cervical cancer published between 2000 and 2022. Citespace and VOS viewer were the primary tools used to identify research focal points, intriguing future patterns, and to evaluate contributions and co-occurrences among authors, institutions, countries, and journals.A total of 1,001 original articles were identified, involving 6,387 authors from 66 countries and 1,474 institutions, and published across 366 academic journals. The United States contributed most significantly. The most productive researcher was Van der Burg SH from Leiden University Medical Center. The International Journal of Cancer and Cancer Research were identified as the most productive and influential journals, respectively. Analysis of co-citation clusters highlighted 25 clusters, primarily focusing on potential predictive biomarkers, dendritic cell-based tumor vaccines, therapeutic HPV vaccinations, peptide-based cancer vaccines, tumor immune microenvironments, and adoptive cell transfer (ACT). The latest significant trends in A/R/M cervical cancer immunotherapy research included ACT, CAR-T, and immune checkpoint inhibitors (ICIs), as revealed by keyword and reference burst detection.This pioneering study provides a detailed landscape of immunotherapy research in A/R/M cervical cancer. It underscores the importance of global collaboration, enriches our understanding of the immunology of A/R/M cervical cancer, expands on potential beneficiaries of immunotherapy, and explores clinical applications of various therapies, including therapeutic vaccines, adoptive cell transfer, and ICIs, particularly in combination with established treatments such as chemotherapy, radiotherapy, and targeted therapy.Copyright © 2024 Duan, Yang, Wang, Zhang, Fu, Li and Yin.